A carregar...
Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis
BACKGROUND: The bevacizumab and irinotecan protocol is considered a standard treatment regimen for recurrent malignant glioma. Recent advances in immunotherapy have hinted that vaccination with dendritic cells could become an alternative salvage therapy for the treatment of recurrent malignant gliom...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5108618/ https://ncbi.nlm.nih.gov/pubmed/27877052 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S112842 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|